FDA Fast-Tracks Psychedelic Drug Reviews After Trump Executive Order

On April 24, 2026 the FDA granted national priority vouchers to Compass Pathways, the Usona Institute and Transcend Therapeutics under its National Priority Voucher pilot, fast-tracking psychedelic medicines for treatment-resistant depression, major depressive disorder and PTSD following President Donald Trump’s executive order.

CNN

Compass Pathways tests synthetic psilocybin for treatment-resistant depression; the Usona Institute runs a psilocybin trial for major depressive disorder; Transcend Therapeutics develops methylone for PTSD. The FDA also cleared a first U.S. early-phase ibogaine study for alcohol-use disorder.

CNN

Trump’s April 20, 2026 executive order directs the FDA to prioritize breakthrough-designated psychedelics and allocates $50 million for state research. The National Priority Voucher pilot began in 2025; the April 24 voucher awards implement the order’s fast-track mandate.

CNN

Proponents say accelerated reviews could expand options for veterans and patients with treatment-resistant depression, PTSD or alcohol-use disorder, easing the mental-health crisis. Faster pathways may prompt insurance and training discussions, but scientific and safety standards remain unchanged.

CNN

FDA Commissioner Marty Makary called for rigorous evidence. HHS Secretary Robert F. Kennedy Jr. pledged accelerated access for veterans. Compass Pathways CEO Kabir Nath cited Phase 3 data; Usona Institute said the voucher shortens review to 1-2 months, keeping standards unchanged. American Psychiatric Association welcomed investment but urged a research-driven approach.

CNN

The American Psychiatric Association warned that fast-tracking could outpace evidence, stressing “solid evidence and patient safety” as priorities. Critics note most psychedelics remain Schedule I, requiring controlled-setting use, and that infrastructure, training and insurance coverage are not yet ready. Psychedelic Medicine Coalition founder Melissa Lavasani urged preparation of protocols before approval.

CNN

Usona Institute claims the voucher can cut review to 1-2 months, yet the FDA stresses unchanged scientific standards, leaving approval timing uncertain. The executive order promises rapid access, but industry leaders admit infrastructure, training and insurance mechanisms remain undeveloped. No efficacy or safety data for ibogaine or methylone have been released.

CNN

• “Compass has generated positive data from two large, well controlled Phase 3 clinical trials.” — Kabir Nath, CEO, Compass Pathways

CNN

• “accelerates FDA review to approximately one to two months,” but “it does not alter scientific or regulatory standards.” — Usona Institute statement

CNN

• “We are accelerating the research, approval, and responsible access to promising mental health treatments – including psychedelic therapies like ibogaine – to confront our nation’s mental health crisis head-on, especially for our veterans,” — Robert F. Kennedy Jr., US Health and Human Services Secretary

CNN

The FDA will issue final guidance for psychedelic sponsors within weeks, detailing data and safety requirements. Voucher holders must complete trials before any approval. State research funded by the $50 million allocation begins later in 2026, shaping future regulatory and reimbursement policies.

CNN